Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Snchez de la Cuesta F
RESULTS VARY FROM PERSON TO PERSON
Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia (abnormal cholesterol levels), and obstructive sleep apnea
The comparison between GLP-1RA and SGLT-2 inhibitors shows no difference in their risk for total death (RR = 1.00, 95% CI 0.911.11)
Metabolism of TAM takes place mainly through two main pathways, 4-hydroxylation and N-demethylation, from which TAM is converted to primary metabolites 4-hydroxy-tamoxifen and N-desmethyl-tamoxifen (Klein et al., 2013)
Should I be extra concerned about vaccinations given they most likely have a reduced ability to detoxify because of this mutation